Assessing Phase III SERENA-6 Results for Camizestrant in Advanced HR-Positive Breast Cancer with Emergent ESR1 Mutation from AstraZeneca

Scheduled for:Dec 30, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist specializing in hormone receptor-positive breast cancer with experience in molecular profiling and endocrine resistance. Ideally involved in clinical trials involving SERDs or CDK4/6 inhibitors, and familiar with implementing ctDNA-guided treatment strategies in clinical practice.

Interview Goal

The interview aims to unpack the significance of the SERENA-6 Phase III trial, which demonstrated a 56% reduction in disease progression or death with camizestrant plus a CDK4/6 inhibitor in HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. Discussion will focus on clinical relevance, implications of ctDNA monitoring, and camizestrant’s positioning as a next-generation SERD.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.